Ieq Capital LLC Makes New Investment in Heartflow, Inc. $HTFL

Ieq Capital LLC bought a new stake in Heartflow, Inc. (NASDAQ:HTFL) during the second quarter, Holdings Channel.com reports. The firm bought 69,778 shares of the company’s stock, valued at approximately $2,047,000.

A number of other hedge funds have also modified their holdings of HTFL. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Heartflow during the 4th quarter worth about $27,000. Russell Investments Group Ltd. purchased a new position in Heartflow during the fourth quarter worth about $45,000. Essential Partners LLC acquired a new stake in shares of Heartflow during the first quarter valued at about $57,000. Legal & General Group Plc purchased a new stake in shares of Heartflow in the 3rd quarter valued at approximately $59,000. Finally, Strs Ohio purchased a new stake in shares of Heartflow in the 4th quarter valued at approximately $99,000.

Heartflow Stock Down 0.6%

Shares of HTFL opened at $49.89 on Wednesday. The company has a market cap of $4.34 billion and a P/E ratio of -27.26. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $51.19. The firm’s 50 day moving average price is $31.36 and its 200 day moving average price is $28.63.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The company had revenue of $64.08 million during the quarter. Heartflow’s revenue was up 47.7% on a year-over-year basis. Research analysts forecast that Heartflow, Inc. will post -0.82 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO John C.M. Farquhar sold 38,900 shares of the business’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $35.00, for a total transaction of $1,361,500.00. Following the completion of the transaction, the chief executive officer directly owned 457,935 shares of the company’s stock, valued at $16,027,725. The trade was a 7.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $41.23, for a total value of $380,099.37. Following the sale, the insider owned 86,459 shares in the company, valued at approximately $3,564,704.57. This trade represents a 9.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 191,271 shares of company stock valued at $7,089,136. 7.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

HTFL has been the subject of a number of research analyst reports. Freedom Capital raised shares of Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. Robert W. Baird set a $45.00 price target on Heartflow in a research note on Friday, August 14th. Canaccord Genuity Group raised their price target on Heartflow from $37.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. Weiss Ratings raised Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 7th. Finally, Benchmark reiterated a “buy” rating on shares of Heartflow in a report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $43.43.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.